JPH0812564A - Skin external preparation - Google Patents
Skin external preparationInfo
- Publication number
- JPH0812564A JPH0812564A JP6168690A JP16869094A JPH0812564A JP H0812564 A JPH0812564 A JP H0812564A JP 6168690 A JP6168690 A JP 6168690A JP 16869094 A JP16869094 A JP 16869094A JP H0812564 A JPH0812564 A JP H0812564A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- una
- gato
- phase
- external preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000000284 extract Substances 0.000 claims abstract description 40
- 235000019096 Proboscidea parviflora Nutrition 0.000 claims abstract description 24
- 230000002087 whitening effect Effects 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 240000006236 Martynia annua Species 0.000 claims abstract 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 34
- 230000000694 effects Effects 0.000 abstract description 17
- 102000003425 Tyrosinase Human genes 0.000 abstract description 12
- 108060008724 Tyrosinase Proteins 0.000 abstract description 12
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 239000006071 cream Substances 0.000 abstract description 6
- 208000012641 Pigmentation disease Diseases 0.000 abstract description 4
- 238000010438 heat treatment Methods 0.000 abstract description 4
- 239000002904 solvent Substances 0.000 abstract description 4
- 241000196324 Embryophyta Species 0.000 abstract description 3
- 206010014970 Ephelides Diseases 0.000 abstract description 3
- 206010042496 Sunburn Diseases 0.000 abstract description 3
- 235000013399 edible fruits Nutrition 0.000 abstract description 3
- 238000001914 filtration Methods 0.000 abstract description 3
- 230000019612 pigmentation Effects 0.000 abstract description 3
- 241000554155 Andes Species 0.000 abstract description 2
- 239000002674 ointment Substances 0.000 abstract description 2
- 238000010992 reflux Methods 0.000 abstract description 2
- 230000002500 effect on skin Effects 0.000 abstract 1
- 239000000706 filtrate Substances 0.000 abstract 1
- 230000003061 melanogenesis Effects 0.000 abstract 1
- 239000012071 phase Substances 0.000 description 37
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 239000000203 mixture Substances 0.000 description 22
- 244000023431 Proboscidea parviflora Species 0.000 description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- 235000019441 ethanol Nutrition 0.000 description 16
- 210000003491 skin Anatomy 0.000 description 14
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 238000009472 formulation Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- -1 methanol and ethanol Chemical class 0.000 description 12
- 239000008346 aqueous phase Substances 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 9
- 230000008099 melanin synthesis Effects 0.000 description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 8
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 7
- 239000003205 fragrance Substances 0.000 description 7
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000004945 emulsification Methods 0.000 description 5
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 5
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 5
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 5
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 5
- 239000002304 perfume Substances 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229940032094 squalane Drugs 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 3
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 2
- 235000011118 potassium hydroxide Nutrition 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 239000004328 sodium tetraborate Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- GFVYDNHWTCHDSN-UHFFFAOYSA-N 14-methylpentadecyl octanoate Chemical compound CCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C GFVYDNHWTCHDSN-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 244000128206 Pyracantha coccinea Species 0.000 description 1
- 235000003105 Pyracantha coccinea Nutrition 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 206010064127 Solar lentigo Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 1
- 229940093767 glabridin Drugs 0.000 description 1
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 1
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- 229940041290 mannose Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000005474 octanoate group Chemical group 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 229960005066 trisodium edetate Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明はウナ・デ・ガト(Una
de Gato)の抽出物を配合する事により、メラ
ニンの生成を抑制し、日焼け後の色素沈着・しみ・そば
かす・肝斑等の予防および改善に有効な皮膚外用剤に関
する。BACKGROUND OF THE INVENTION The present invention relates to Una de Gato (Una).
The present invention relates to a skin external preparation that is effective in preventing and improving pigmentation, spots, freckles, and liver spots after sunburn by suppressing the production of melanin by incorporating an extract of de Gato).
【0002】[0002]
【従来の技術】皮膚のしみなどの発生機序については一
部不明な点もあるが、一般には、ホルモンの異常や日光
からの紫外線の刺激が原因となってメラニン色素が形成
され、これが皮膚内に異常沈着するものと考えられてい
る。皮膚の着色の原因となるこのメラニン色素は、表皮
と真皮との間にあるメラニン細胞(メラノサイト)内の
メラニン生成顆粒(メラノソーム)において生産され、
生成したメラニンは、浸透作用により隣接細胞へ拡散す
る。このメラノサイト内における生化学反応は、次のよ
うなものと推定されている。すなわち、必須アミノ酸で
あるチロシンが酵素チロシナーゼの作用によりドーパキ
ノンとなり、これが酵素的または非酵素的酸化作用によ
り赤色色素および無色色素を経て黒色のメラニンへ変化
する過程がメラニン色素の生成過程である。従って、反
応の第1段階であるチロシナーゼの作用を抑制すること
が、メラニン生成の抑制に重要である。BACKGROUND OF THE INVENTION Although there are some unclear points about the mechanism of skin spots and the like, in general, melanin pigments are formed due to hormonal abnormalities and irritation of ultraviolet rays from the sun, and this is the skin. It is thought to be abnormally deposited inside. This melanin pigment, which causes skin coloring, is produced in melanin-producing granules (melanosomes) in melanocytes (melanocytes) between the epidermis and dermis,
The generated melanin diffuses into adjacent cells by the osmotic effect. The biochemical reaction in this melanocyte is presumed to be as follows. That is, the process in which tyrosine, which is an essential amino acid, becomes dopaquinone by the action of the enzyme tyrosinase, and this is converted to black melanin via the red and colorless pigments by the enzymatic or non-enzymatic oxidation action is the melanin pigment formation process. Therefore, suppressing the action of tyrosinase, which is the first step of the reaction, is important for suppressing melanin production.
【0003】[0003]
【発明が解決しようとする課題】しかしチロシナーゼ作
用を抑制する化合物はハイドロキノンを除いてはその効
果の発現がきわめて緩慢であるため、皮膚色素沈着の改
善効果が十分でない。一方、ハイドロキノンは効果は一
応認められているが、感作性があるため、一般には使用
が制限されている。そこでその安全性を向上させるた
め、高級脂肪酸のモノエステルやアルキルモノエーテル
などにする試み(特開昭58−154507号公報)が
なされているが、エステル類は体内の加水分解酵素によ
って分解されるため必ずしも安全とはいいがたく、また
エーテル類も安全性の面で充分に満足するものが得られ
ていない。However, compounds that suppress the tyrosinase action, except for hydroquinone, have very slow onset of their effects, so that the effect of improving skin pigmentation is not sufficient. On the other hand, although hydroquinone is recognized as having an effect, its use is generally restricted because of its sensitizing properties. Therefore, in order to improve its safety, attempts have been made to use higher fatty acid monoesters or alkyl monoethers (JP-A-58-154507), but the esters are decomposed by a hydrolase in the body. Therefore, it is not always safe, and ethers have not been sufficiently satisfactory in terms of safety.
【0004】[0004]
【課題を解決するための手段】そこで本発明者らはこれ
らの問題を解決するものとして広く種々の物質について
メラニン生成抑制効果を調べた結果、ウナ・デ・ガト
(Una de Gato)の抽出物がメラニン生成抑
制作用およびチロシナーゼ阻害作用を有していることを
見い出し、本発明を完成するに至った。ウナ・デ・ガト
(Una deGato)の抽出物のメラニン生成抑制
作用等に関する報告はこれまでになく、美白剤への応用
も全く知られていない。本発明者らは上記知見に基づい
て本発明を完成するに至った。Therefore, as a result of investigating the melanin production inhibitory effect of various substances as a solution to these problems, the present inventors have found that the extract of Una de Gato It was found that the compound has a melanin production inhibitory action and a tyrosinase inhibitory action, and completed the present invention. There has been no report on the melanin production inhibitory action of the extract of Una de Gato, and its application to a whitening agent has not been known at all. The present inventors have completed the present invention based on the above findings.
【0005】すなわち本発明は、ウナ・デ・ガト(Un
a de Gato)の抽出物を配合することを特徴と
する皮膚外用剤である。本発明における外用剤は、特に
美白用皮膚外用剤であることを好適とする。That is, the present invention relates to Una de Gato (Un
a de Gato) extract is incorporated into the skin external preparation. The external preparation of the present invention is preferably a whitening skin external preparation.
【0006】以下、本発明の構成について詳述する。本
発明に用いられるウナ・デ・ガト(Una de Ga
to)は、南アメリカ、特にアンデスなどの乾性草原、
牧草などに生える植物である。本発明に用いられる抽出
物は上記、葉と茎または果実等、ウナ・デ・ガト全草を
抽出溶媒と共に浸漬または加熱還流した後、濾過し、濃
縮して得られる。本発明に用いられる抽出溶媒は、通常
抽出に用いられる溶媒であれば何でもよく、特にメタノ
ール、エタノール等のアルコール類、含水アルコール
類、アセトン、酢酸エチルエステル等の有機溶媒を単独
あるいは組み合わせて用いることができる。The structure of the present invention will be described in detail below. Una de Ga used in the present invention
to) is a dry grassland in South America, especially the Andes,
It is a plant that grows on grass. The extract used in the present invention is obtained by immersing or heating and refluxing whole plants of Una de Gato such as leaves, stems or fruits, and then filtering and concentrating. The extraction solvent used in the present invention may be any solvent that is usually used for extraction, and in particular, alcohols such as methanol and ethanol, hydrous alcohols, acetone, and organic solvents such as acetic acid ethyl ester may be used alone or in combination. You can
【0007】本発明におけるウナ・デ・ガト抽出物の配
合量は、外用剤全量中、乾燥物として0.005〜2
0.0重量%、好ましくは0.01〜10.0重量%で
ある。0.005重量%未満であると、本発明でいう効
果が十分に発揮されず、20.0重量%を超えると製剤
化が難しいので好ましくない。また、10.0重量%以
上配合してもさほど大きな効果の向上はみられない。The amount of the Una de Gato extract blended in the present invention is 0.005 to 2 as a dry product in the total amount of the external preparation.
It is 0.0% by weight, preferably 0.01 to 10.0% by weight. If it is less than 0.005% by weight, the effect of the present invention is not sufficiently exhibited, and if it exceeds 20.0% by weight, formulation is difficult, which is not preferable. Further, even if it is blended in an amount of 10.0% by weight or more, the effect is not so much improved.
【0008】また、本発明の皮膚外用剤には、上記必須
成分以外に、通常化粧品や医薬品等の皮膚外用剤に用い
られる成分、例えば、その他の美白剤、保湿剤、酸化防
止剤、油性成分、紫外線吸収剤、界面活性剤、増粘剤、
アルコール類、粉末成分、色材、水性成分、水、各種皮
膚栄養剤等を必要に応じて適宜配合することができる。In addition to the above-mentioned essential components, the external preparation for skin of the present invention is a component that is usually used in external preparations for skin such as cosmetics and pharmaceuticals, for example, other whitening agents, moisturizers, antioxidants and oily components. , UV absorber, surfactant, thickener,
Alcohols, powder components, coloring materials, aqueous components, water, various skin nutrients and the like can be appropriately blended as necessary.
【0009】その他、エデト酸二ナトリウム、エデト酸
三ナトリウム、クエン酸ナトリウム、ポリリン酸ナトリ
ウム、メタリン酸ナトリウム、グルコン酸等の金属封鎖
剤、カフェイン、タンニン、ベラパミル、トラネキサム
酸およびその誘導体、甘草抽出物、グラブリジン、火棘
の果実の熱水抽出物、各種生薬、酢酸トコフェロール、
グリチルリチン酸およびその誘導体またはその塩等の薬
剤、ビタミンC、アスコルビン酸リン酸マグネシウム、
アスコルビン酸グルコシド、アルブチン、コウジ酸等の
他の美白剤、グルコース、フルクトース、マンノース、
ショ糖、トレハロース等の糖類なども適宜配合すること
ができる。In addition, sequestering agents such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, gluconic acid, caffeine, tannin, verapamil, tranexamic acid and its derivatives, licorice extraction Substance, glabridin, hot water extract of fruits of fire thorns, various crude drugs, tocopherol acetate,
Drugs such as glycyrrhizic acid and its derivatives or salts thereof, vitamin C, magnesium ascorbate phosphate,
Other whitening agents such as ascorbic acid glucoside, arbutin, kojic acid, glucose, fructose, mannose,
Sugars such as sucrose and trehalose can also be appropriately added.
【0010】本発明の皮膚外用剤とは、例えば軟膏、ク
リーム、乳液、ローション、パック、浴用剤等、従来皮
膚外用剤に用いるものであればいずれでもよく、剤型は
特に問わない。The external preparation for skin of the present invention may be any ointment, cream, emulsion, lotion, pack, bath agent or the like as long as it is a conventional external preparation for skin, and its form is not particularly limited.
【0011】[0011]
【実施例】次に実施例によって本発明をさらに詳細に説
明する。尚、本発明はこれにより限定されるものではな
い。配合量は重量%である。実施例に先立ち、本発明の
植物抽出物のメラニン抑制効果、チロシナーゼ活性阻害
効果および美白効果に関する試験方法とその結果につい
て説明する。Next, the present invention will be described in more detail by way of examples. The present invention is not limited to this. The blending amount is% by weight. Prior to Examples, test methods and results of the melanin suppressing effect, tyrosinase activity inhibiting effect and whitening effect of the plant extract of the present invention will be described.
【0012】試験方法およびその結果 1.試料の調製 ウナ・デ・ガト(Una de Gato)の茎および
枝部分50gを、室温で1週間エタノールに浸漬し、抽
出液を濃縮し、エタノール抽出物1.3gを得た。この
抽出物をDMSOに1%溶かし、この溶液を希釈して濃
度を調整し、これを用いて以下の実験を行った。 Test Method and Results 1. Preparation of Sample 50 g of the stem and branch portion of Una de Gato was immersed in ethanol at room temperature for 1 week, and the extract was concentrated to obtain 1.3 g of an ethanol extract. This extract was dissolved in DMSO at a concentration of 1%, the solution was diluted to adjust the concentration, and the following experiment was conducted using this.
【0013】2.細胞培養法 マウス由来のB16メラノーマ培養細胞を使用した。1
0%FBSおよびテオフィリン(0.09mg/ml)
を含むイーグルMEM培地中でCO2インキュベーター
(95%空気,5%二酸化炭素)内、37℃の条件下で
培養した。培養24時間後に試料溶液を終濃度(抽出乾
燥物換算濃度)で10-2〜10-5重量%になるように添
加し、さらに3日間培養を続け、以下の方法でメラニン
生成量の視感判定およびチロシナーゼ活性阻害効果を測
定した。2. Cell Culture Method B16 melanoma cultured cells derived from mouse were used. 1
0% FBS and theophylline (0.09 mg / ml)
The cells were cultured in an Eagle MEM medium containing C. in a CO 2 incubator (95% air, 5% carbon dioxide) at 37 ° C. After 24 hours of culturing, the sample solution was added so as to have a final concentration (concentration of extracted dry matter) of 10 -2 to 10 -5 % by weight, culturing was continued for another 3 days, and the melanin production amount was visually sensed by the following method. The determination and the tyrosinase activity inhibitory effect were measured.
【0014】3.メラニン量の視感測定 ウエルのプレートの蓋の上に拡散板を置き、倒立顕微鏡
で細胞内のメラニン量を観察し、ウナ・デ・ガト抽出物
を添加していない試料(基準)の場合と比較した。その
結果を表1に表示した。また、参考例として、すでにメ
ラニン生成抑制作用のあることが知られているケイガイ
(シソ科オドリコソウ亜科)抽出物についても上記と同
様の試験を行った。その結果を併せて表1に示す。また
表中、毒性とあるのは、細胞毒性のあることを示す。3. Visual measurement of melanin amount Place a diffusion plate on the lid of the well plate, observe the intracellular melanin amount with an inverted microscope, and compare it with the sample (reference) to which the Una de Gato extract was not added. Compared. The results are shown in Table 1. In addition, as a reference example, the same test as above was carried out on an extract of Kaigai (Lamiaceae, Odorikosou Subfamily), which is already known to have an action of suppressing melanin production. The results are also shown in Table 1. Further, in the table, "toxic" means that it is cytotoxic.
【0015】<判定基準> ○:白(メラニン量) △:やや白(メラニン量) ×:基準(メラニン量)<Judgment Criteria> ◯: White (amount of melanin) Δ: Slightly white (amount of melanin) ×: Reference (amount of melanin)
【0016】4.チロシナーゼ活性の測定 測定前にウエル中の培地は除去し、PBS100μlで
2回洗う。各ウエルに45μlの1%トライトン−X
(ローム・アンド・ハース社製商品名、界面活性剤)を
含むPBSを加える。1分間プレートを振動させ、よく
細胞膜を破壊し、マイクロプレートリーダーで475n
mの吸光度を測定してこれを0分時の吸光度とした。そ
の後、すばやく5μlの10mMのL−DOPA溶液を
加えて、37℃のインキュベーターに移し、60分間反
応させた。1分間プレートを振動させ、60分時の吸光
度(475nm)を測定した。ウナ・デ・ガト抽出物を
添加していない試料(コントロール)の場合の0分時と
60分時の吸光度差に対するウナ・デ・ガト抽出物添加
試料の前記吸光度差の減少分をチロシナーゼ活性阻害率
(%)とした。その結果を表1に示す。また、参考例と
して、すでにチロシナーゼ活性阻害作用のあることが知
られているケイガイのエタノール抽出物についても上記
と同様の試験を行った。その結果を併せて表1に示す。
なお、表中、毒性とあるのは、細胞毒性が認められたこ
とを示し、−は、コントロールに比べて、危険率5%以
内で有意な差が認められなかったことを意味する。4. Measurement of tyrosinase activity Before the measurement, the medium in the wells is removed, and the wells are washed twice with 100 μl of PBS. 45 μl of 1% Triton-X in each well
(Rohm and Haas product name, surfactant) containing PBS is added. Shake the plate for 1 minute, break the cell membrane well, and use a microplate reader for 475n.
The absorbance at m was measured, and this was taken as the absorbance at 0 minutes. Then, 5 μl of 10 mM L-DOPA solution was quickly added, and the mixture was transferred to an incubator at 37 ° C. and reacted for 60 minutes. The plate was shaken for 1 minute, and the absorbance (475 nm) at 60 minutes was measured. Inhibition of tyrosinase activity by the decrease in the absorbance difference of the sample to which the Una de Gato extract was added relative to the absorbance difference at 0 minute and 60 minutes in the case of the sample (control) to which the Una de Gato extract was not added The rate (%) was used. Table 1 shows the results. Further, as a reference example, the same test as above was carried out on an ethanol extract of mussel, which is already known to have a tyrosinase activity inhibitory action. The results are also shown in Table 1.
In the table, "toxic" means that cytotoxicity was observed, and "-" means that no significant difference was observed within a risk rate of 5% as compared with the control.
【0017】[0017]
【表1】 ─────────────────────────────────── 試験 メラニン生成視感評価 チロシナーゼ活性阻害率(%) ──────── ──────────────────────── 濃度(重量%) 10-5 10-4 10-3 10-2 10-5 10-4 10-3 10-2 ─────────────────────────────────── ウナ・デ・ガト抽出物 × △ × × 28 30 33 30 ケイガイ抽出物 × × × × − − − 55 ───────────────────────────────────[Table 1] ─────────────────────────────────── Test Melanin production Visual evaluation Tyrosinase activity inhibition rate ( %) ──────── ──────────────────────── concentration (wt%) 10 -5 10 -4 10 -3 10 - 2 10 -5 10 -4 10 -3 10 -2 ─────────────────────────────────── Una ・De Gato extract × △ × × 28 30 33 30 Kaigai extract × × × × − − − 55 ─────────────────────────── ─────────
【0018】5.美白効果試験 [試験方法]夏期の太陽光に4時間(1日2時間で2日
間)晒された被験者40名の上腕内側部皮膚を対象とし
て太陽光に晒された日の5日後より各試料を朝夕1回ず
つ4週間塗布した。パネルを一群8名に分けて、5群と
し下記に示す処方で試験を行った。 (アルコール相) 95%エチルアルコール 55.0 重量% ポリオキシエチレン(25モル)硬化ヒマシ油エーテル 2.0 酸化防止剤・防腐剤 適量 香料 適量 薬剤(表2記載) (水相) グリセリン 5.0 ヘキサメタリン酸ナトリウム 適量 イオン交換水 残余 <製法>水相、アルコール相をそれぞれ調製し、その後
両者を混合して可溶化する。5. Whitening test [Test method] 40 subjects exposed to sunlight in summer for 4 hours (2 hours per day for 2 days) each sample from 5 days after the day of sun exposure to the skin of the upper arm inner skin Was applied once each morning and evening for 4 weeks. The panel was divided into 8 groups, and 5 groups were prepared, and the tests were conducted according to the formulations shown below. (Alcohol phase) 95% Ethyl alcohol 55.0% by weight Polyoxyethylene (25 mol) hydrogenated castor oil ether 2.0 Antioxidant / preservative proper amount Fragrance proper amount drug (listed in Table 2) (water phase) glycerin 5.0 Sodium hexametaphosphate Suitable amount Ion-exchanged water Residue <Production method> An aqueous phase and an alcohol phase are prepared, respectively, and then both are mixed and solubilized.
【0019】[評価方法]使用後の淡色化効果を下記の
判定基準に基づいて判定した。 <判定基準> ◎:被験者のうち著効および有効の示す割合が80%以
上の場合 ○:被験者のうち著効および有効の示す割合が50%〜
80%未満の場合 △:被験者のうち著効および有効の示す割合が30%〜
50%未満の場合 ×:被験者のうち著効および有効の示す割合が30%未
満の場合[Evaluation Method] The lightening effect after use was judged based on the following judgment criteria. <Judgment Criteria> ⊚: When the rate of marked efficacy and efficacy among subjects is 80% or more ◯: The rate of marked efficacy and efficacy among subjects is 50% to
In the case of less than 80% Δ: Remarkable and effective proportion of subjects is 30% to
When less than 50% x: When the ratio of markedly effective or effective among the subjects is less than 30%
【0020】上記試験法記載の配合組成からなる試料を
調製し、表2記載の薬剤を用いて美白効果を比較した。
結果は表2に示す。Samples having the blending composition described in the above test method were prepared and the whitening effect was compared using the agents shown in Table 2.
The results are shown in Table 2.
【0021】[0021]
【表2】 ────────────────────────── 薬 剤 配合量(重量%) 効 果 ────────────────────────── 無添加 − × ハイドロキノン 1.0 △ ウナ・デ・ガト抽出物 0.1 ○ ウナ・デ・ガト抽出物 1.0 ○ ウナ・デ・ガト抽出物 10.0 ◎ ──────────────────────────[Table 2] ────────────────────────── Drug compounding amount (% by weight) Effect ────────── ──────────────── Additive- × Hydroquinone 1.0 △ Una de Gato extract 0.1 ○ Una de Gato extract 1.0 ○ Una de・ Gato extract 10.0 ◎ ──────────────────────────
【0022】なお、表2のウナ・デ・ガト抽出物は、ウ
ナ・デ・ガト(Una de Gato)の全草をエタ
ノール中で加熱還元した後、濾過、濃縮乾燥して得たも
のである。The Una de Gato extract in Table 2 was obtained by heating and reducing whole grass of Una de Gato in ethanol, filtering and concentrating and drying. .
【0023】表2より明らかな様に、太陽光に晒された
後の効果はウナ・デ・ガト抽出物を添加した方が過剰の
メラニン色素の沈着を防ぎ、色黒になることを予防する
ことが認められた。As is clear from Table 2, the effect after exposure to sunlight is that the addition of Una de Gato extract prevents the deposition of excess melanin pigment and prevents darkening. Was confirmed.
【0024】実施例1 クリーム (処方) ステアリン酸 5.0 重量% ステアリルアルコール 4.0 イソプロピルミリステート 18.0 グリセリンモノステアリン酸エステル 3.0 プロピレングリコール 10.0 ウナ・デ・ガトメタノール抽出物 0.01 苛性カリ 0.2 亜硫酸水素ナトリウム 0.01 防腐剤 適量 香料 適量 イオン交換水 残余 (製法)イオン交換水にプロピレングリコールとウナ・
デ・ガトメタノール抽出物と苛性カリを加え溶解し、加
熱して70℃に保つ(水相)。他の成分を混合し加熱融
解して70℃に保つ(油相)。水相に油相を徐々に加
え、全部加え終わってからしばらくその温度に保ち反応
を起こさせる。その後、ホモミキサーで均一に乳化し、
よくかきまぜながら30℃まで冷却する。Example 1 Cream (Formulation) Stearic acid 5.0% by weight Stearyl alcohol 4.0 Isopropyl myristate 18.0 Glycerin monostearate 3.0 Propylene glycol 10.0 Una de gatomethanol extract 0 .01 Caustic potassium 0.2 Sodium bisulfite 0.01 Preservative Suitable amount Perfume Suitable amount Ion-exchanged water Residual (production method) Propylene glycol and una
De-gato-methanol extract and caustic potash were added and dissolved, and heated and kept at 70 ° C (aqueous phase). The other ingredients are mixed, heated and melted and maintained at 70 ° C. (oil phase). The oil phase is gradually added to the water phase, and after the addition is completed, the temperature is maintained for a while to cause the reaction. After that, homogenize with a homomixer,
Cool to 30 ° C while stirring well.
【0025】 実施例2 クリーム (処方) ステアリン酸 2.0 重量% ステアリルアルコール 7.0 水添ラノリン 2.0 スクワラン 5.0 2−オクチルドデシルアルコール 6.0 ポリオキシエチレン(25モル)セチルアルコールエーテル 3.0 グリセリンモノステアリン酸エステル 2.0 プロピレングリコール 5.0 ウナ・デ・ガトエタノール抽出物 0.05 亜硫酸水素ナトリウム 0.03 エチルパラベン 0.3 香料 適量 イオン交換水 残余 (製法)イオン交換水にプロピレングリコールを加え、
加熱して70℃に保つ(水相)。他の成分を混合し加熱
融解して70℃に保つ(油相)。水相に油相を加え予備
乳化を行い、ホモミキサーで均一に乳化した後、よくか
きまぜながら30℃まで冷却する。Example 2 Cream (Formulation) Stearic acid 2.0% by weight Stearyl alcohol 7.0 Hydrogenated lanolin 2.0 Squalane 5.0 2-Octyldodecyl alcohol 6.0 Polyoxyethylene (25 mol) cetyl alcohol ether 3.0 Glycerin monostearate 2.0 Propylene glycol 5.0 Una de gatoethanol extract 0.05 Sodium hydrogen sulfite 0.03 Ethylparaben 0.3 Perfume proper amount Ion-exchanged water Residual (production method) Ion-exchanged water Add propylene glycol to
Heat to maintain 70 ° C (aqueous phase). The other ingredients are mixed, heated and melted and maintained at 70 ° C. (oil phase). The oil phase is added to the aqueous phase to carry out preliminary emulsification, and the mixture is uniformly emulsified with a homomixer and then cooled to 30 ° C. with thorough stirring.
【0026】 実施例3 クリーム (処方) 固形パラフィン 5.0 重量% ミツロウ 10.0 ワセリン 15.0 流動パラフィン 41.0 グリセリンモノステアリン酸エステル 2.0 ポリオキシエチレン(20モル)ソルビタンモノラウリン酸エステル 2.0 石けん粉末 0.1 硼砂 0.2 ウナ・デ・ガトアセトン抽出物 0.05 ウナ・デ・ガトエタノール抽出物 0.05 亜硫酸水素ナトリウム 0.03 エチルパラベン 0.3 香料 適量 イオン交換水 残余 (製法)イオン交換水に石けん粉末と硼砂を加え、加熱
溶解して70℃に保つ(水相)。他の成分を混合し加熱
融解して70℃に保つ(油相)。水相に油相をかきまぜ
ながら徐々に加え反応を行う。反応終了後、ホモミキサ
ーで均一に乳化し、乳化後よくかきまぜながら30℃ま
で冷却する。Example 3 Cream (Formulation) Solid paraffin 5.0% by weight Beeswax 10.0 Vaseline 15.0 Liquid paraffin 41.0 Glycerin monostearate 2.0 Polyoxyethylene (20 mol) sorbitan monolaurate 2 0.0 Soap powder 0.1 Borax 0.2 Una de gatoacetone extract 0.05 Una de gatoethanol extract 0.05 Sodium hydrogen sulfite 0.03 Ethylparaben 0.3 Perfume proper amount Ion-exchanged water residue ( Manufacturing method) Soap powder and borax are added to ion-exchanged water, and the mixture is heated and melted and kept at 70 ° C (aqueous phase). The other ingredients are mixed, heated and melted and maintained at 70 ° C. (oil phase). The oil phase is stirred into the water phase and gradually added to carry out the reaction. After the reaction is completed, the mixture is uniformly emulsified with a homomixer, and after emulsification, the mixture is cooled to 30 ° C. with thorough stirring.
【0027】 実施例4 乳液 (処方) ステアリン酸 2.5 重量% セチルアルコール 1.5 ワセリン 5.0 流動パラフィン 10.0 ポリオキシエチレン(10モル)モノオレイン酸エステル 2.0 ポリエチレングリコール1500 3.0 トリエタノールアミン 1.0 カルボキシビニルポリマー 0.05 (商品名:カーボポール941,B.F.Goodrich Chemical company) ウナ・デ・ガト酢酸エチルエステル抽出物 0.01 亜硫酸水素ナトリウム 0.01 エチルパラベン 0.3 香料 適量 イオン交換水 残余 (製法)少量のイオン交換水にカルボキシビニルポリマ
ーを溶解する(A相)。残りのイオン交換水にポリエチ
レングリコール1500とトリエタノールアミンを加
え、加熱溶解して70℃に保つ(水相)。他の成分を混
合し加熱融解して70℃に保つ(油相)。水相に油相を
加え予備乳化を行い、A相を加えホモミキサーで均一乳
化し、乳化後よくかきまぜながら30℃まで冷却する。Example 4 Emulsion (formulation) Stearic acid 2.5 wt% Cetyl alcohol 1.5 Vaseline 5.0 Liquid paraffin 10.0 Polyoxyethylene (10 mol) monooleate 2.0 Polyethylene glycol 1500 3. 0 triethanolamine 1.0 carboxyvinyl polymer 0.05 (trade name: Carbopol 941, BFGoodrich Chemical company) Una de Gato acetic acid ethyl ester extract 0.01 sodium bisulfite 0.01 ethylparaben 0.3 fragrance Appropriate amount Ion-exchanged water Residual (manufacturing method) Dissolve carboxyvinyl polymer in a small amount of ion-exchanged water (Phase A). Polyethylene glycol 1500 and triethanolamine were added to the remaining ion-exchanged water, and the mixture was heated and dissolved and maintained at 70 ° C (aqueous phase). The other ingredients are mixed, heated and melted and maintained at 70 ° C. (oil phase). The oil phase is added to the aqueous phase for preliminary emulsification, the phase A is added and the mixture is homogenized with a homomixer, and after emulsification, the mixture is cooled to 30 ° C. while being well stirred.
【0028】 実施例5 乳液 (処方) マイクロクリスタリンワックス 1.0 重量% 密ロウ 2.0 ラノリン 20.0 流動パラフィン 10.0 スクワラン 5.0 ソルビタンセスキオレイン酸エステル 4.0 ポリオキシエチレン(20モル)ソルビタンモノオレイン酸エステル 1.0 プロピレングリコール 7.0 ウナ・デ・ガトアセトン抽出物 10.0 亜硫酸水素ナトリウム 0.01 エチルパラベン 0.3 香料 適量 イオン交換水 残余 (製法)イオン交換水にプロピレングリコールを加え、
加熱して70℃に保つ(水相)。他の成分を混合し、加
熱融解して70℃に保つ(油相)。油相をかきまぜなが
らこれに水相を徐々に加え、ホモミキサーで均一に乳化
する。乳化後よくかきまぜながら30℃まで冷却する。Example 5 Emulsion (Formulation) Microcrystalline wax 1.0% by weight Beeswax 2.0 Lanolin 20.0 Liquid paraffin 10.0 Squalane 5.0 Sorbitan sesquioleate 4.0 Polyoxyethylene (20 mol) ) Sorbitan monooleate 1.0 Propylene glycol 7.0 Una de gatoacetone extract 10.0 Sodium hydrogen sulfite 0.01 Ethylparaben 0.3 Fragrance Ion-exchanged water Residual (production method) Propylene glycol on ion-exchanged water And add
Heat to maintain 70 ° C (aqueous phase). The other ingredients are mixed, heated and melted and kept at 70 ° C. (oil phase). While stirring the oil phase, the aqueous phase is gradually added to this and the mixture is uniformly emulsified with a homomixer. After emulsification, cool to 30 ° C while stirring well.
【0029】 実施例6 ゼリー (処方) 95%エチルアルコール 10.0 重量% ジプロピレングリコール 15.0 ポリオキシエチレン(50モル)オレイルアルコールエーテル 2.0 カルボキシビニルポリマー 1.0 (商品名:カーボポール940,B.F.Goodrich Chemical company) 苛性ソーダ 0.15 L−アルギニン 0.1 ウナ・デ・ガト50%エタノール水溶液抽出物 7.0 2-ヒドロキシ-4-メトキシベンゾフェノンスルホン酸ナトリウム 0.05 エチレンジアミンテトラアセテート・3ナトリウム・2水 0.05 メチルパラベン 0.2 香料 適量 イオン交換水 残余 (製法)イオン交換水にカーボポール940を均一に溶
解し、一方、95%エタノールにウナ・デ・ガト50%
エタノール水溶液抽出物、ポリオキシエチレン(50モ
ル)オレイルアルコールエーテルを溶解し、水相に添加
する。次いで、その他の成分を加えたのち苛性ソーダ、
L−アルギニンで中和させ増粘する。Example 6 Jelly (formulation) 95% ethyl alcohol 10.0 wt% dipropylene glycol 15.0 polyoxyethylene (50 mol) oleyl alcohol ether 2.0 carboxyvinyl polymer 1.0 (trade name: Carbopol 940, BFGoodrich Chemical company) Caustic soda 0.15 L-Arginine 0.1 Una de Gato 50% ethanol aqueous solution extract 7.0 2-Hydroxy-4-methoxybenzophenone sulfonate sodium 0.05 Ethylenediaminetetraacetate-3 sodium・ 2 water 0.05 Methylparaben 0.2 Fragrance Suitable amount Ion-exchanged water Residual (manufacturing method) Carbopol 940 is uniformly dissolved in ion-exchanged water, while Una de Gato 50% in 95% ethanol
An aqueous ethanol solution extract and polyoxyethylene (50 mol) oleyl alcohol ether are dissolved and added to the aqueous phase. Next, after adding other ingredients, caustic soda,
Thicken by neutralizing with L-arginine.
【0030】 実施例7 美容液 (処方) (A相) エチルアルコール(95%) 10.0 重量% ポリオキシエチレン(20モル)オクチルドデカノール 1.0 パントテニールエチルエーテル 0.1 ウナ・デ・ガトメタノール抽出物 1.5 メチルパラベン 0.15 (B相) 水酸化カリウム 0.1 (C相) グリセリン 5.0 ジプロピレングリコール 10.0 亜硫酸水素ナトリウム 0.03 カルボキシビニルポリマー 0.2 (商品名:カーボポール940,B.F.Goodrich Chemical company) 精製水 残余 (製法)A相、C相をそれぞれ均一に溶解し、C相にA
相を加えて可溶化する。次いでB相を加えたのち充填を
行う。Example 7 Beauty Serum (Formulation) (Phase A) Ethyl Alcohol (95%) 10.0% by Weight Polyoxyethylene (20 mol) Octyldodecanol 1.0 Pantotenyl Ethyl Ether 0.1 Una De Gatomethanol extract 1.5 Methylparaben 0.15 (Phase B) Potassium hydroxide 0.1 (Phase C) Glycerin 5.0 Dipropylene glycol 10.0 Sodium bisulfite 0.03 Carboxyvinyl polymer 0.2 (trade name) : Carbopol 940, BFGoodrich Chemical company) Purified water Residue (Production method) A phase and C phase are uniformly dissolved, and A is added to C phase.
Add phase and solubilize. Next, phase B is added and then filling is performed.
【0031】実施例8 パック (処方) (A相) ジプロピレングリコール 5.0 重量% ポリオキシエチレン(60モル)硬化ヒマシ油 5.0 (B相) ウナ・デ・ガトメタノール抽出物 0.01 オリーブ油 5.0 酢酸トコフェロール 0.2 エチルパラベン 0.2 香料 0.2 (C相) 亜硫酸水素ナトリウム 0.03 ポリビニルアルコール 13.0 (ケン化度90、重合度2,000) エタノール 7.0 精製水 残余 (製法)A相、B相、C相をそれぞれ均一に溶解し、A
相にB相を加えて可溶化する。次いでこれをC相に加え
たのち充填を行う。Example 8 Pack (formulation) (Phase A) 5.0% by weight dipropylene glycol Polyoxyethylene (60 mol) hydrogenated castor oil 5.0 (Phase B) Una de gatomethanol extract 0.01 Olive oil 5.0 Tocopherol acetate 0.2 Ethylparaben 0.2 Perfume 0.2 (Phase C) Sodium bisulfite 0.03 Polyvinyl alcohol 13.0 (Saponification degree 90, degree of polymerization 2,000) Ethanol 7.0 Purification Water Residue (Production method) A phase, B phase, and C phase are uniformly dissolved,
Phase B is added to the phase to solubilize it. Next, this is added to phase C and then filled.
【0032】実施例9 固形ファンデーション (処方) タルク 43.1 重量% カオリン 15.0 セリサイト 10.0 亜鉛華 7.0 二酸化チタン 3.8 黄色酸化鉄 2.9 黒色酸化鉄 0.2 スクワラン 8.0 イソステアリン酸 4.0 モノオレイン酸POEソルビタン 3.0 オクタン酸イソセチル 2.0 ウナ・デ・ガトエタノール抽出物 1.0 防腐剤 適量 香料 適量 (製法)タルク〜黒色酸化鉄の粉末成分をブレンダーで
十分混合し、これにスクワラン〜オクタン酸イソセチル
の油性成分、ウナ・デ・ガトエタノール抽出物、防腐
剤、香料を加え良く混練した後、容器に充填、成型す
る。Example 9 Solid Foundation (Formulation) Talc 43.1% by weight Kaolin 15.0 Sericite 10.0 Zinc white 7.0 Titanium dioxide 3.8 Yellow iron oxide 2.9 Black iron oxide 0.2 Squalane 8 0.0 Isostearic acid 4.0 POE sorbitan monooleate 3.0 Isocetyl octanoate 2.0 Una de gatoethanol extract 1.0 Preservative proper amount Fragrance appropriate amount (production method) Blending talc to black iron oxide powder component Sufficiently mixed with squalane to isocetyl octoate, the oil extract of Una de Gato ethanol, preservative, and fragrance, and kneaded well.
【0033】 実施例10 乳化型ファンデーション(クリームタイプ) (処方) (粉体部) 二酸化チタン 10.3 重量% セリサイト 5.4 カオリン 3.0 黄色酸化鉄 0.8 ベンガラ 0.3 黒色酸化鉄 0.2 (油相) デカメチルシクロペンタシロキサン 11.5 流動パラフィン 4.5 ポリオキシエチレン変性ジメチルポリシロキサン 4.0 (水相) 精製水 50.0 1,3−ブチレングルコール 4.5 ウナ・デ・ガトエタノール抽出物 1.5 ソルビタンセスキオレイン酸エステル 3.0 防腐剤 適量 香料 適量 (製法)水相を加熱攪拌後、十分に混合粉砕した粉体部
を添加してホモミキサー処理する。更に加熱混合した油
相を加えてホモミキサー処理した後、攪拌しながら香料
を添加して室温まで冷却する。Example 10 Emulsion type foundation (cream type) (Formulation) (Powder part) Titanium dioxide 10.3% by weight Sericite 5.4 Kaolin 3.0 Yellow iron oxide 0.8 Bengala 0.3 Black iron oxide 0.2 (oil phase) decamethylcyclopentasiloxane 11.5 liquid paraffin 4.5 polyoxyethylene-modified dimethylpolysiloxane 4.0 (water phase) purified water 50.0 1,3-butylene glycol 4.5 una De-gatoethanol extract 1.5 Sorbitan sesquioleate 3.0 Preservative proper amount Perfume proper amount (Production method) After heating and stirring the aqueous phase, the powder portion thoroughly mixed and pulverized is added and treated with a homomixer. Further, the heated and mixed oil phase is added and subjected to a homomixer treatment, and then a fragrance is added with stirring and cooled to room temperature.
【0034】[0034]
【発明の効果】以上説明したように、本発明の皮膚外用
剤は、メラニン生成抑制作用およびチロシナーゼ活性阻
害作用を有しており、日焼け後の色素沈着・しみ・そば
かす・肝斑等の淡色化、美白に優れた効果を有すると共
に、安全性にも優れた皮膚外用剤である。Industrial Applicability As described above, the external preparation for skin of the present invention has a melanin production inhibitory action and a tyrosinase activity inhibitory action, and it causes lightening of pigmentation, stains, freckles, melasma etc. after sunburn. It is an external preparation for skin that has excellent whitening effect and safety.
フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 A61K 35/78 ADA C 8217−4C (72)発明者 長沼 雅子 神奈川県横浜市港北区新羽町1050番地 株 式会社資生堂第一リサーチセンター内 (72)発明者 福田 實 神奈川県横浜市港北区新羽町1050番地 株 式会社資生堂第一リサーチセンター内Continuation of the front page (51) Int.Cl. 6 Identification number Reference number within the agency FI Technical indication location A61K 35/78 ADA C 8217-4C (72) Inventor Masako Naganuma 1050 Shinba-cho, Kohoku-ku, Yokohama-shi, Kanagawa Prefecture Company Shiseido Daiichi Research Center (72) Inventor Minoru Fukuda 1050 Shinba-cho, Kohoku-ku, Yokohama-shi, Kanagawa Stock Company Shiseido Daiichi Research Center
Claims (3)
o)の抽出物を配合することを特徴とする皮膚外用剤。1. Una de Gat
An external preparation for skin, comprising the extract of o).
005〜20.0重量%である請求項1記載の皮膚外用
剤。2. The blending amount of the extract of Una de Gato is 0.
The external preparation for skin according to claim 1, which is 005 to 20.0% by weight.
2記載の皮膚外用剤。3. The external preparation for skin according to claim 1, which is an external preparation for whitening skin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6168690A JPH0812564A (en) | 1994-06-29 | 1994-06-29 | Skin external preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6168690A JPH0812564A (en) | 1994-06-29 | 1994-06-29 | Skin external preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0812564A true JPH0812564A (en) | 1996-01-16 |
Family
ID=15872663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6168690A Pending JPH0812564A (en) | 1994-06-29 | 1994-06-29 | Skin external preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0812564A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2824270A1 (en) * | 2001-10-11 | 2002-11-08 | Coletica | USE OF AN UNCARIA TOMENTOSA LIANE EXTRACT AS A LIPOLYTIC OR SLIMMING ACTIVE INGREDIENT |
| US20120269910A1 (en) * | 2001-05-03 | 2012-10-25 | Basf Beauty Care Solutions France S.A.S. | Method for Testing a Substance Which is Potentially Active in the Field of Lipolysis and its Mainly Cosmetic Use |
| KR101245813B1 (en) * | 2006-11-03 | 2013-03-20 | 주식회사 엘지생활건강 | Cosmetic composition comprising lycii fructus extract and uncaria tomentosa extract for whitening of the skin |
-
1994
- 1994-06-29 JP JP6168690A patent/JPH0812564A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120269910A1 (en) * | 2001-05-03 | 2012-10-25 | Basf Beauty Care Solutions France S.A.S. | Method for Testing a Substance Which is Potentially Active in the Field of Lipolysis and its Mainly Cosmetic Use |
| US8741359B2 (en) * | 2001-05-03 | 2014-06-03 | Basf Beauty Care Solutions France S.A.S. | Method for testing a substance which is potentially active in the field of lipolysis and its mainly cosmetic use |
| FR2824270A1 (en) * | 2001-10-11 | 2002-11-08 | Coletica | USE OF AN UNCARIA TOMENTOSA LIANE EXTRACT AS A LIPOLYTIC OR SLIMMING ACTIVE INGREDIENT |
| KR101245813B1 (en) * | 2006-11-03 | 2013-03-20 | 주식회사 엘지생활건강 | Cosmetic composition comprising lycii fructus extract and uncaria tomentosa extract for whitening of the skin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3481386B2 (en) | Skin whitening preparation for external use | |
| JPH0930946A (en) | Beautifying and whitening dermal preparation for external use | |
| JPH11246347A (en) | Preparation for external use for skin bleaching | |
| JPH0812560A (en) | Skin external preparation | |
| JPH0812561A (en) | Beautifying and whitening skin preparation for external use | |
| JPH0812566A (en) | Inhibitor of tyrosinase activity | |
| JPH08310939A (en) | Beautifying and whitening dermal preparation for external use | |
| JPH0930945A (en) | Dermal preparation for external use | |
| JPH0812549A (en) | Skin external preparation | |
| JPH0930949A (en) | Beautifying and whitening dermal preparation for external use | |
| JP3140357B2 (en) | Skin whitening agent | |
| JPH0812552A (en) | Skin external preparation | |
| JPH0930948A (en) | Beautifying and whitening dermal preparation for external use | |
| JP3527406B2 (en) | Skin whitening external preparation | |
| JPH08301758A (en) | Skin preparation for external use | |
| JPH0812564A (en) | Skin external preparation | |
| JPH0920635A (en) | Whitening skin preparation for external use | |
| JPH0812557A (en) | Skin external preparation | |
| JPH0812550A (en) | Skin external preparation | |
| JPH0920636A (en) | Skin preparation for external use | |
| JPH0920634A (en) | Whitening skin preparation for external use | |
| JPH0995420A (en) | Preparation for external use for skin | |
| JP3263246B2 (en) | External preparation for skin | |
| JPH0812554A (en) | Skin external preparation | |
| JP3354031B2 (en) | External preparation for skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20020618 |